ABBOTT LABORATORIES AND NAPRO BIOTHERAPEUTICS FILE PACLITAXEL ANDA
Advertisement
Abbott Laboratories (NYSE: ABT) and NaPro BioTherapeutics, Inc. (Nasdaq: NPRO) announced today that they have filed an Abbreviated New Drug Application (ANDA) with the U.S. food and Drug Administration (FDA) for paclitaxel, the most widely used anticancer compound in the United States.
"Abbott is building a superior portfolio of oncology products," said Christopher B. Begley, senior vice president, hospital products, Abbott Laboratories. "Submitting the paclitaxel ANDA is a major milestone in Abbott's plan to expand our presence in the oncology market."
"We are very hopeful that soon oncologists and cancer patients in the United States will have another high quality paclitaxel option," commented Leonard P. Shaykin, chairman and chief executive officer, NaPro BioTherapeutics.
Most read news
Other news from the department research and development

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Whatman Completes The Acquisition Of The Assets Of HemaSure Inc.

European business restructure of Shimadzu completed - Integrated in European business structure
Abbott named on Top 10 "Best places to work for scientists" by the Scientist Magazine
Bending helps to control nanomaterials
Microfluidic applications centre Dolomite exceeds expectations
Hexion Files Suit against Credit Suisse and Deutsche Bank for Failure to Fund Merger with Huntsman
Producing solar power with impure silicon - Researchers have developed a technique that allows the use of less pure silicon in solar cells
ThyssenKrupp stops business with Iran
